These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 19200354)

  • 1. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
    Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
    Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.
    Mohammadi L; Vreeswijk MP; Oldenburg R; van den Ouweland A; Oosterwijk JC; van der Hout AH; Hoogerbrugge N; Ligtenberg M; Ausems MG; van der Luijt RB; Dommering CJ; Gille JJ; Verhoef S; Hogervorst FB; van Os TA; Gómez García E; Blok MJ; Wijnen JT; Helmer Q; Devilee P; van Asperen CJ; van Houwelingen HC
    BMC Cancer; 2009 Jun; 9():211. PubMed ID: 19563646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
    Lee E; McKean-Cowdin R; Ma H; Chen Z; Van Den Berg D; Henderson BE; Bernstein L; Ursin G
    Breast Cancer Res; 2008; 10(1):R19. PubMed ID: 18284688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer.
    Choi MC; Jang JH; Jung SG; Park H; Joo WD; Song SH; Lee C; Lee JH
    Int J Gynecol Cancer; 2018 Feb; 28(2):308-315. PubMed ID: 29240602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Significant Unclassified Variants in
    Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
    Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
    Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
    Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reclassification of
    Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
    J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in classification of genetic variants in BRCA1 and BRCA2.
    Kast K; Wimberger P; Arnold N
    Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
    Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
    J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
    Cifuentes-C L; Rivera-Herrera AL; Barreto G
    Colomb Med (Cali); 2019 Sep; 50(3):163-175. PubMed ID: 32284662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.